CYP450 3A4 / 3A5 Genotyping

Cytochrome P450 3A4/5 (CYP3A4/3A5) acts on approximately half of all drugs in clinical use. About 8% of Caucasians have a slow acting, intermediate metabolizer form of CYP3A4 (CYP3A4 *22). [34]

Prevalence of CYP3A5 variants differs widely by ethnic origin. Approximately 11-12% of Asian and African Americans have non-functional CYP3A5 alleles (CYP3A5 *6, *7). CYP3A4 and CYP3A5 are closely related and may process many of the same drugs. Substrates include opioid pain medications, statins, chemotherapeutic drugs, and combined oral contraceptives.[35]

Genelex offers improved detection rates using a Cytochrome P450 3A4 mutation panel and a Cytochrome P450 3A5 DNA test. These tests each identify common clinically relevant alleles in their respective genes (CYP3A4: *1B,*22. CYP3A5: *3,*6,*7) in PCR-multiplex format. Analytical specificity and sensitivity for detection of these mutations are >99%.

Genelex offers improved detection rates using a Cytochrome P450 3A4 mutation panel and a Cytochrome P450 3A5 DNA test. These tests each identify one clinically-relevant single nucleotide variant in their respective genes in PCR-multiplex format. Analytical specificity and sensitivity for detection of these mutations are >99%.

Indication for CYP3A4/CYP3A5 Testing

For individuals with a personal or family history of adverse drug reactions to medications metabolized by CYP3A4/3A5.

Insurance Coverage

CPT Codes: CYP3A4 and CYP3A5 Mutation DNA Analysis: 81230; 81231 (provided as guidance only).